Geode Capital Management’s IO Biotech IOBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-33,307
| Closed | -$1.96K | – | 4514 |
|
|
2026
Q1 | $1.96K | Hold |
33,307
| – | – | ﹤0.01% | 4508 |
|
|
2025
Q4 | $20.3K | Hold |
33,307
| – | – | ﹤0.01% | 4386 |
|
|
2025
Q3 | $12.1K | Hold |
33,307
| – | – | ﹤0.01% | 4440 |
|
|
2025
Q2 | $46.3K | Hold |
33,307
| – | – | ﹤0.01% | 4236 |
|
|
2025
Q1 | $36.3K | Hold |
33,307
| – | – | ﹤0.01% | 4251 |
|
|
2024
Q4 | $30.6K | Hold |
33,307
| – | – | ﹤0.01% | 4322 |
|
|
2024
Q3 | $35K | Hold |
33,307
| – | – | ﹤0.01% | 4328 |
|
|
2024
Q2 | $39K | Hold |
33,307
| – | – | ﹤0.01% | 4328 |
|
|
2024
Q1 | $58.3K | Buy |
33,307
+20,577
| +162% | +$35.7K | ﹤0.01% | 4290 |
|
|
2023
Q4 | $23.9K | Hold |
12,730
| – | – | ﹤0.01% | 4483 |
|
|
2023
Q3 | $17.6K | Hold |
12,730
| – | – | ﹤0.01% | 4644 |
|
|
2023
Q2 | $24.9K | Hold |
12,730
| – | – | ﹤0.01% | 4630 |
|
|
2023
Q1 | $23.8K | Hold |
12,730
| – | – | ﹤0.01% | 4669 |
|
|
2022
Q4 | $29K | Hold |
12,730
| – | – | ﹤0.01% | 4710 |
|
|
2022
Q3 | $34K | Hold |
12,730
| – | – | ﹤0.01% | 4828 |
|
|
2022
Q2 | $59K | Hold |
12,730
| – | – | ﹤0.01% | 4740 |
|
|
2022
Q1 | $67K | Buy |
12,730
+1,557
| +14% | +$10.3K | ﹤0.01% | 4753 |
|
|
2021
Q4 | $73K | Buy |
+11,173
| New | +$108K | ﹤0.01% | 4795 |
|
Geode Capital Management's IOBT Position: Q2 2026 in Review
Geode Capital Management sold out of IO Biotech (IOBT) in Q2 2026, closing a stake of 33,307 shares — an estimated $1.96K sold.
Geode Capital Management first reported a position in IOBT in Q4 2021 and held it in 18 quarters. The position peaked at $73K in Q4 2021. 0 funds tracked by Wall St. Rank hold IOBT as of Q2 2026.
- Geode Capital Management reported no remaining IO Biotech position as of Q2 2026 after selling out during the quarter.
- Geode Capital Management sold 33,307 IO Biotech shares in Q2 2026, an estimated $1.96K.
- Geode Capital Management first reported a position in IO Biotech in Q4 2021 and held it in 18 quarters.
- Geode Capital Management's IO Biotech position peaked at $73K in Q4 2021.
- 0 funds tracked by Wall St. Rank held IO Biotech as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.